Verrix Boosts Leadership in Preparation for Commercialization of Novel Biological Indicator System
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Apr 9, 2019--Verrix, developer of solutions for rapid and accurate sterilization confirmation, is expanding its leadership team in preparation for commercialization of its EVA™ Biological Indicator (BI) System. Vice President of Research & Development Kok-Hwee Ng, Ph.D., and Vice President of Regulatory & Quality Aiying Sun will help advance the company’s technology designed to protect patients from life-threatening infections.
“Verrix is growing at a rapid pace as we prepare for commercialization of the EVA BI System,” said Cameron Rouns, CEO of Verrix. “We are excited to welcome Kok-Hwee and Aiying to the senior management group at this pivotal time for the company. Their extensive expertise, proven track record, and passion for emerging technology will be invaluable as we introduce our first-to-market platform and continue our pipeline development activities.”
Verrix was founded in 2013 to develop sterility assurance products and technologies for the healthcare market and has doubled in size in the last year. The company has a unique heritage—with foundational technology originally invented and developed at NASA’s Jet Propulsion Laboratory. The first BI system based on the advanced Verrix technology is expected to be introduced in 2019.
“While medical technology has advanced in recent years, currently used BI technology has not kept pace with evolving user needs,” Dr. Ng said. “I look forward to working with Verrix to develop this novel technology into a meaningful healthcare solution that addresses both the clinical and operational challenges posed by healthcare-associated infections.”
Dr. Ng has more than two decades of leadership and management experience in the medical device industry, working with both startup and Fortune 500 companies such as St. Jude Medical, Stryker, Boston Scientific, Johnson & Johnson, Baxter International, General Electric Medical Systems, and OrthoSensor.
Ms. Sun brings significant expertise in quality assurance and regulatory affairs to the Verrix team. She has more than 25 years of experience with medical device and pharmaceutical companies, working closely with U.S. and international regulatory authorities to establish and continuously improve quality management systems to ensure compliance with applicable regulations and standards.
For full bios and to learn more about the Verrix leadership team, click here.
Verrix is a San Clemente, Calif.-based medical device company that is using the most advanced technologies to help protect patients from healthcare-associated infections. The foundational sterility assurance technology, originally discovered at NASA’s Jet Propulsion Laboratory, integrates cutting-edge optical physics, chemistry spectroscopy, and molecular biology. Based on scientific expertise and close partnerships with healthcare professionals, Verrix is developing market-changing solutions for sterility assurance, environmental monitoring, and infection control. Visit www.verrix.com for more information.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190409005293/en/
CONTACT: Media Contact
Andrea Sampson, Sullivan & Sampson PR
firstname.lastname@example.org, 714/374-6174Erin Manning, Vice President, Marketing, Verrix
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY HOSPITALS INFECTIOUS DISEASES MEDICAL DEVICES OTHER HEALTH GENERAL HEALTH
Copyright Business Wire 2019.
PUB: 04/09/2019 08:32 AM/DISC: 04/09/2019 08:32 AM